{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:30:35Z","timestamp":1792089035458,"version":"4.4.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR073324"],"award-info":[{"award-number":["AR073324"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AR064194"],"award-info":[{"award-number":["T32AR064194"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK126944"],"award-info":[{"award-number":["DK126944"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR060772"],"award-info":[{"award-number":["AR060772"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR075990"],"award-info":[{"award-number":["AR075990"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009012","name":"Veterans Affairs San Diego Healthcare System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Linked metabolic and cardiovascular comorbidities are prevalent in hyperuricemia and gout. For mechanistic insight into impact on inflammatory processes and cardiometabolic risk factors of xanthine oxidase inhibitor urate-lowering therapy (ULT) titration to target, we performed a prospective study of gout serum metabolomes from a ULT trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sera of gout patients meeting the 2015 ACR\/EULAR gout classification criteria (<jats:italic>n<\/jats:italic>\u2009=\u200920) and with hyperuricemia were studied at time zero and weeks 12 and 24 of febuxostat or allopurinol dose titration ULT. Ultrahigh performance liquid chromatography-tandem mass spectroscopy acquired the serum spectra. Data were assessed using the Metabolon and Metaboloanalyst software. Lipolysis validation assays were done in febuxostat and\/or colchicine-treated 3T3-L1 differentiated adipocytes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serum urate decreased from time zero (8.21 \u00b11.139 SD) at weeks 12 (5.965 \u00b1 1.734 SD) and 24 (5.655 \u00b11.763 SD). Top metabolites generated by changes in nucleotide and certain amino acid metabolism and polyamine pathways were enriched at 12 and 24\u2009weeks ULT, respectively. Decreases in multiple fatty acid metabolites were observed at 24\u2009weeks, linked with obesity. In cultured adipocytes, febuxostat significantly decreased while colchicine increased the lipolytic response to \u03b2-adrenergic-agonism or TNF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Metabolomic profiles linked xanthine oxidase inhibitor-based ULT titration to target with reduced serum free fatty acids. In vitro validation studies revealed that febuxostat, but not colchicine, reduced lipolysis in cultured adipocytes. Since soluble urate, xanthine oxidase inhibitor treatment, and free fatty acids modulate inflammation, our findings suggest that by suppressing lipolysis, ULT could regulate inflammation in gout and comorbid metabolic and cardiovascular disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02852-4","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T09:15:43Z","timestamp":1658740543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes"],"prefix":"10.1186","volume":"24","author":[{"given":"Monica","family":"Guma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyamin","family":"Dadpey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Coras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlett","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Thorisdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bittleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Liu-Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-7473","authenticated-orcid":false,"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"issue":"6","key":"2852_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71(6):991\u20139.","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"2852_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679\u201387 e1.","journal-title":"Am J Med."},{"issue":"12","key":"2852_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","volume":"15","author":"Y Sato","year":"2019","unstructured":"Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Ejaz AA, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019;15(12):767\u201375.","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"2852_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"RJ Johnson","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71(6):851\u201365.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"2852_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41584-019-0334-3","volume":"16","author":"LAB Joosten","year":"2020","unstructured":"Joosten LAB, Crisan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16(2):75\u201386.","journal-title":"Nat Rev Rheumatol."},{"issue":"1","key":"2852_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41590-020-00845-6","volume":"22","author":"M Divangahi","year":"2021","unstructured":"Divangahi M, Aaby P, Khader SA, Barreiro LB, Bekkering S, Chavakis T, et al. Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol. 2021;22(1):2\u20136.","journal-title":"Nat Immunol."},{"issue":"2","key":"2852_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.ajkd.2017.05.004","volume":"70","author":"PM Ferraro","year":"2017","unstructured":"Ferraro PM, Curhan GC. Serum uric acid and risk of kidney stones. Am J Kidney Dis. 2017;70(2):158\u20139.","journal-title":"Am J Kidney Dis."},{"key":"2852_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","volume":"80","author":"C Borghi","year":"2020","unstructured":"Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1\u201311.","journal-title":"Eur J Intern Med."},{"issue":"4","key":"2852_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.ajkd.2020.09.009","volume":"77","author":"AG Stack","year":"2021","unstructured":"Stack AG, Dronamraju N, Parkinson J, Johansson S, Johnsson E, Erlandsson F, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis. 2021;77(4):481\u20139.","journal-title":"Am J Kidney Dis."},{"key":"2852_CR10","doi-asserted-by":"crossref","unstructured":"Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose intake, serum uric acid, and cardiometabolic disorders: a critical review.\u00a0Nutrients. 2017;9(4):395.","DOI":"10.3390\/nu9040395"},{"issue":"8","key":"2852_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/15257770802257952","volume":"27","author":"C Gersch","year":"2008","unstructured":"Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008;27(8):967\u201378.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"issue":"5","key":"2852_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101\u20136.","journal-title":"Hypertension."},{"issue":"8","key":"2852_CR13","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1096\/fj.13-243634","volume":"28","author":"C Cicerchi","year":"2014","unstructured":"Cicerchi C, Li N, Kratzer J, Garcia G, Roncal-Jimenez CA, Tanabe K, et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J. 2014;28(8):3339\u201350.","journal-title":"FASEB J."},{"issue":"11","key":"2852_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048801","volume":"7","author":"MA Lanaspa","year":"2012","unstructured":"Lanaspa MA, Cicerchi C, Garcia G, Li N, Roncal-Jimenez CA, Rivard CJ, et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS One. 2012;7(11):e48801.","journal-title":"PLoS One."},{"issue":"48","key":"2852_CR15","doi-asserted-by":"publisher","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","volume":"287","author":"MA Lanaspa","year":"2012","unstructured":"Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287(48):40732\u201344.","journal-title":"J Biol Chem."},{"issue":"1","key":"2852_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41598-020-57784-3","volume":"10","author":"T Nishikawa","year":"2020","unstructured":"Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020;10(1):815.","journal-title":"Sci Rep."},{"issue":"1","key":"2852_CR17","doi-asserted-by":"publisher","first-page":"G42","DOI":"10.1152\/ajpgi.00443.2014","volume":"309","author":"Y Nakatsu","year":"2015","unstructured":"Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A, et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015;309(1):G42\u201351.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"6","key":"2852_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"2852_CR19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/febs.14768","volume":"286","author":"J Lu","year":"2019","unstructured":"Lu J, Sun M, Wu X, Yuan X, Liu Z, Qu X, et al. Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis. FEBS J. 2019;286(7):1346\u201359.","journal-title":"FEBS J."},{"issue":"2","key":"2852_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/ATVBAHA.111.234559","volume":"32","author":"A Kushiyama","year":"2012","unstructured":"Kushiyama A, Okubo H, Sakoda H, Kikuchi T, Fujishiro M, Sato H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol. 2012;32(2):291\u20138.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"8","key":"2852_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00296-019-04342-4","volume":"22","author":"J Wu","year":"2019","unstructured":"Wu J, Zhang YP, Qu Y, Jie LG, Deng JX, Yu QH. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. Int J Rheum Dis. 2019;22(8):1445\u201351.","journal-title":"Int J Rheum Dis."},{"issue":"5","key":"2852_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2016.1","volume":"12","author":"M Guma","year":"2016","unstructured":"Guma M, Tiziani S, Firestein GS. Metabolomics in rheumatic diseases: desperately seeking biomarkers. Nat Rev Rheumatol. 2016;12(5):269\u201381.","journal-title":"Nat Rev Rheumatol."},{"key":"2852_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","volume":"68","author":"S Timilsina","year":"2018","unstructured":"Timilsina S, Brittan K, O'Dell JR, Brophy M, Davis-Karim A, Henrie AM, et al. Design and rationale for the Veterans Affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d trial. Contemp Clin Trials. 2018;68:102\u20138.","journal-title":"Contemp Clin Trials."},{"key":"2852_CR24","doi-asserted-by":"crossref","unstructured":"O'Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative effectiveness of allopurinol and febuxostat in gout management.\u00a0NEJM Evid. 2022;1(3):10.","DOI":"10.1056\/EVIDoa2100028"},{"issue":"10","key":"2852_CR25","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/art.39254","volume":"67","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557\u201368.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"2852_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.bbalip.2011.07.006","volume":"1811","author":"O Quehenberger","year":"2011","unstructured":"Quehenberger O, Armando AM, Dennis EA. High sensitivity quantitative lipidomics analysis of fatty acids in biological samples by gas chromatography-mass spectrometry. Biochim Biophys Acta. 2011;1811(11):648\u201356.","journal-title":"Biochim Biophys Acta."},{"issue":"W1","key":"2852_CR27","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gky310","volume":"46","author":"J Chong","year":"2018","unstructured":"Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018;46(W1):W486\u2013W94.","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2852_CR28","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1002\/cpbi.86","volume":"68","author":"J Chong","year":"2019","unstructured":"Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinformatics. 2019;68(1):e86.","journal-title":"Curr Protoc Bioinformatics."},{"issue":"D1","key":"2852_CR29","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353\u2013D61.","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"2852_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"2852_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"7758","key":"2852_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655\u201362.","journal-title":"Nature."},{"key":"2852_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fmicb.2017.00268","volume":"8","author":"T Shao","year":"2017","unstructured":"Shao T, Shao L, Li H, Xie Z, He Z, Wen C. Combined signature of the fecal microbiome and metabolome in patients with gout. Front Microbiol. 2017;8:268.","journal-title":"Front Microbiol."},{"key":"2852_CR34","doi-asserted-by":"publisher","first-page":"20602","DOI":"10.1038\/srep20602","volume":"6","author":"Z Guo","year":"2016","unstructured":"Guo Z, Zhang J, Wang Z, Ang KY, Huang S, Hou Q, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep. 2016;6:20602.","journal-title":"Sci Rep."},{"issue":"11","key":"2852_CR35","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.tem.2020.02.012","volume":"31","author":"Y Liu","year":"2020","unstructured":"Liu Y, Hou Y, Wang G, Zheng X, Hao H. Gut microbial metabolites of aromatic amino acids as signals in host-microbe interplay. Trends Endocrinol Metab. 2020;31(11):818\u201334.","journal-title":"Trends Endocrinol Metab."},{"issue":"4","key":"2852_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","volume":"17","author":"A Lavelle","year":"2020","unstructured":"Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"10","key":"2852_CR37","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41587-019-0233-9","volume":"37","author":"T Wilmanski","year":"2019","unstructured":"Wilmanski T, Rappaport N, Earls JC, Magis AT, Manor O, Lovejoy J, et al. Blood metabolome predicts gut microbiome alpha-diversity in humans. Nat Biotechnol. 2019;37(10):1217\u201328.","journal-title":"Nat Biotechnol."},{"issue":"2-3","key":"2852_CR38","first-page":"123","volume":"2","author":"AA Spector","year":"1984","unstructured":"Spector AA. Plasma lipid transport. Clin Physiol Biochem. 1984;2(2-3):123\u201334.","journal-title":"Clin Physiol Biochem."},{"issue":"2","key":"2852_CR39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/oxfordjournals.jbchem.a121917","volume":"101","author":"M Kawakami","year":"1987","unstructured":"Kawakami M, Murase T, Ogawa H, Ishibashi S, Mori N, Takaku F, et al. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J Biochem. 1987;101(2):331\u20138.","journal-title":"J Biochem."},{"issue":"4","key":"2852_CR40","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1172\/JCI113733","volume":"82","author":"HF Starnes Jr","year":"1988","unstructured":"Starnes HF Jr, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF, et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest. 1988;82(4):1321\u20135.","journal-title":"J Clin Invest."},{"issue":"1","key":"2852_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1541-4337.12401","volume":"18","author":"N Ma","year":"2019","unstructured":"Ma N, Ma X. Dietary Amino Acids and the Gut-Microbiome-Immune Axis: Physiological metabolism and therapeutic prospects. Compr Rev Food Sci Food Saf. 2019;18(1):221\u201342.","journal-title":"Compr Rev Food Sci Food Saf."},{"issue":"7","key":"2852_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101267","volume":"9","author":"RL Jump","year":"2014","unstructured":"Jump RL, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, et al. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One. 2014;9(7):e101267.","journal-title":"PLoS One."},{"key":"2852_CR43","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8664","volume":"8","author":"X Liu","year":"2020","unstructured":"Liu X, Lv Q, Ren H, Gao L, Zhao P, Yang X, et al. The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia. PeerJ. 2020;8:e8664.","journal-title":"PeerJ."},{"key":"2852_CR44","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.3389\/fmicb.2018.02233","volume":"9","author":"Y Yu","year":"2018","unstructured":"Yu Y, Liu Q, Li H, Wen C, He Z. Alterations of the gut microbiome associated with the treatment of hyperuricaemia in male rats. Front Microbiol. 2018;9:2233.","journal-title":"Front Microbiol."},{"key":"2852_CR45","doi-asserted-by":"crossref","unstructured":"Nie C, He T, Zhang W, Zhang G, Ma X. Branched chain amino acids: Beyond Nutrition Metabolism.\u00a0Int J Mol Sci. 2018;19(4):954.","DOI":"10.3390\/ijms19040954"},{"issue":"4","key":"2852_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.4517","volume":"24","author":"JA Gilbert","year":"2018","unstructured":"Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med. 2018;24(4):392\u2013400.","journal-title":"Nat Med."},{"issue":"5","key":"2852_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s10038-020-00863-0","volume":"66","author":"X Yu","year":"2021","unstructured":"Yu X, Wang T, Huang S, Zeng P. Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis. J Hum Genet. 2021;66(5):465\u201373.","journal-title":"J Hum Genet."},{"key":"2852_CR48","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1038\/srep04554","volume":"4","author":"J Nomura","year":"2014","unstructured":"Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014;4:4554.","journal-title":"Sci Rep."},{"issue":"4","key":"2852_CR49","doi-asserted-by":"publisher","first-page":"F710","DOI":"10.1152\/ajprenal.00454.2007","volume":"294","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294(4):F710\u20138.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"7","key":"2852_CR50","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/RHU.0000000000000168","volume":"20","author":"G Saviola","year":"2014","unstructured":"Saviola G, Benucci M, Abdi-Ali L, Sacco S, Cera I, Rossini M. Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients? J Clin Rheumatol. 2014;20(7):394\u20135.","journal-title":"J Clin Rheumatol."},{"issue":"4","key":"2852_CR51","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","volume":"64","author":"X Wan","year":"2016","unstructured":"Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925\u201332.","journal-title":"J Hepatol."},{"issue":"1","key":"2852_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12876-020-01189-z","volume":"20","author":"S Chen","year":"2020","unstructured":"Chen S, Chen D, Yang H, Wang X, Wang J, Xu C. Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p\/FGF21 axis. BMC Gastroenterol. 2020;20(1):39.","journal-title":"BMC Gastroenterol."},{"key":"2852_CR53","doi-asserted-by":"publisher","first-page":"8197325","DOI":"10.1155\/2016\/8197325","volume":"2016","author":"K Sodhi","year":"2016","unstructured":"Sodhi K, Hilgefort J, Banks G, Gilliam C, Stevens S, Ansinelli HA, et al. Uric acid-induced adipocyte dysfunction is attenuated by HO-1 upregulation: potential role of antioxidant therapy to target obesity. Stem Cells Int. 2016;2016:8197325.","journal-title":"Stem Cells Int."},{"issue":"12","key":"2852_CR54","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1042\/CS20200580","volume":"134","author":"M Su","year":"2020","unstructured":"Su M, Sun L, Li W, Liu H, Liu Y, Wei Y, et al. Metformin alleviates hyperuricaemia-induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging. Clin Sci (Lond). 2020;134(12):1537\u201353.","journal-title":"Clin Sci (Lond)."},{"issue":"3","key":"2852_CR55","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1074\/jbc.M208307200","volume":"278","author":"K Okamoto","year":"2003","unstructured":"Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278(3):1848\u201355.","journal-title":"J Biol Chem."},{"issue":"8","key":"2852_CR56","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41366-020-0598-3","volume":"44","author":"AP Demidowich","year":"2020","unstructured":"Demidowich AP, Levine JA, Apps R, Cheung FK, Chen J, Fantoni G, et al. Colchicine\u2019s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial. Int J Obes (Lond). 2020;44(8):1793\u20139.","journal-title":"Int J Obes (Lond)."},{"key":"2852_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.toxlet.2020.09.018","volume":"334","author":"Y Shi","year":"2020","unstructured":"Shi Y, Li J, Yang P, Niu Z, Wei L, Chen L, et al. Colchicine increases intestinal permeability, suppresses inflammatory responses, and alters gut microbiota in mice. Toxicol Lett. 2020;334:66\u201377.","journal-title":"Toxicol Lett."},{"key":"2852_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.biochi.2015.10.024","volume":"125","author":"P Morigny","year":"2016","unstructured":"Morigny P, Houssier M, Mouisel E, Langin D. Adipocyte lipolysis and insulin resistance. Biochimie. 2016;125:259\u201366.","journal-title":"Biochimie."},{"issue":"5","key":"2852_CR59","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrm2391","volume":"9","author":"A Guilherme","year":"2008","unstructured":"Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367\u201377.","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"26","key":"2852_CR60","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.3748\/wjg.v13.i26.3540","volume":"13","author":"K Qureshi","year":"2007","unstructured":"Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2007;13(26):3540\u201353.","journal-title":"World J Gastroenterol."},{"issue":"5","key":"2852_CR61","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1042\/BCJ20190468","volume":"477","author":"A Yang","year":"2020","unstructured":"Yang A, Mottillo EP. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. Biochem J. 2020;477(5):985\u20131008.","journal-title":"Biochem J."},{"key":"2852_CR62","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","volume":"10","author":"F Zatterale","year":"2019","unstructured":"Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2019;10:1607.","journal-title":"Front Physiol."},{"issue":"8","key":"2852_CR63","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/jir.2019.0014","volume":"39","author":"CC Chan","year":"2019","unstructured":"Chan CC, Damen M, Alarcon PC, Sanchez-Gurmaches J, Divanovic S. Inflammation and immunity: from an adipocyte\u2019s perspective. J Interferon Cytokine Res. 2019;39(8):459\u201371.","journal-title":"J Interferon Cytokine Res."},{"issue":"4","key":"2852_CR64","doi-asserted-by":"publisher","first-page":"G484","DOI":"10.1152\/ajpgi.00151.2019","volume":"317","author":"D Xu","year":"2019","unstructured":"Xu D, Lv Q, Wang X, Cui X, Zhao P, Yang X, et al. Hyperuricemia is associated with impaired intestinal permeability in mice. Am J Physiol Gastrointest Liver Physiol. 2019;317(4):G484\u2013G92.","journal-title":"Am J Physiol Gastrointest Liver Physiol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02852-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02852-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02852-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T10:06:17Z","timestamp":1658743577000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02852-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2852"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02852-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial and ancillary study were approved by the VA Institutional Board Review, and all subjects signed an informed written consent for both studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RT: research grant: Astra-Zeneca; consulting: SOBI, Selecta, Horizon, Allena, Astra-ZenecaMG: research grant: Pfizer, NovartisRLB, RC, SMR, BD, HT, DB, KL: none","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}